RLYB Insider Trading (Rallybio)
Insider Ownership Percentage: N/A
Insider Buying (Last 12 Months): $238,740.40
Insider Selling (Last 12 Months): $5,915,500.00
Rallybio Share Price & Price History
Current Price: $7.54
Price Change: ▼ Price Decrease of -0.01 (-0.13%)
As of 07/1/2022 04:59 PM ET
Tailor an Options Trading Strategy to Fit Your Needs
From RJO Futures | Ad
This guide will help you identify and execute an options trading strategy that fits your specific needs and risk profile.
Take your trading to the next level with the Options Strategy Guide.
Download your FREE Options Strategy Guide Today.
Rallybio Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 6/3/2022 | Kush Parmar | Director | Sell | 150,000 | $12.50 | $1,875,000.00 | 1,251,755 |  |
| 5/23/2022 | Kush Parmar | Director | Sell | 100,000 | $13.00 | $1,300,000.00 | 1,302,084 | |
| 3/21/2022 | Jeffrey M. Fryer | Insider | Buy | 3,000 | $8.04 | $24,120.00 | | |
| 2/8/2022 | Opportunities I L.P. 5Am | Major Shareholder | Sell | 210,000 | $13.05 | $2,740,500.00 | | |
| 1/19/2022 | Jeffrey M. Fryer | Insider | Buy | 1,400 | $8.70 | $12,180.00 | | |
| 1/12/2022 | Stephen Uden | Insider | Buy | 5,000 | $10.55 | $52,750.00 | | |
| 1/10/2022 | Martin Mackay | CEO | Buy | 5,504 | $10.10 | $55,590.40 | | |
| 1/7/2022 | Jeffrey M. Fryer | Insider | Buy | 10,000 | $9.41 | $94,100.00 | | |
Tailor an Options Trading Strategy to Fit Your Needs
From RJO Futures | Ad
This guide will help you identify and execute an options trading strategy that fits your specific needs and risk profile.
Take your trading to the next level with the Options Strategy Guide.
Download your FREE Options Strategy Guide Today.
Rallybio Institutional Trading History
| Reporting Date | Hedge Fund | Shares Held | Market Value | % of Portfolio | Quarterly Change in Shares | Ownership in Company | Details |
|---|
| 5/27/2022 | Walleye Capital LLC | 59,543 | $0.42M | 0.0% | N/A | 0.185% |  |
| 5/17/2022 | Walleye Capital LLC | 59,543 | $0.42M | 0.0% | N/A | 0.185% | |
| 5/16/2022 | California State Teachers Retirement System | 7,694 | $54K | 0.0% | +124.8% | 0.024% | |
| 5/16/2022 | Goldman Sachs Group Inc. | 15,289 | $0.11M | 0.0% | +17.0% | 0.048% | |
| 5/16/2022 | State Street Corp | 158,573 | $1.11M | 0.0% | +114.8% | 0.494% | |
| 5/16/2022 | Novo Holdings A S | 435,944 | $3.04M | 0.1% | N/A | 1.357% | |
| 5/13/2022 | Renaissance Technologies LLC | 52,715 | $0.37M | 0.0% | N/A | 0.164% | |
| 5/13/2022 | Northern Trust Corp | 131,432 | $0.92M | 0.0% | +113.5% | 0.409% | |
| 5/13/2022 | Charles Schwab Investment Management Inc. | 45,581 | $0.32M | 0.0% | +183.5% | 0.142% | |
| 5/13/2022 | American International Group Inc. | 8,984 | $63K | 0.0% | +134.9% | 0.028% | |
| 5/13/2022 | Tekla Capital Management LLC | 2,195,010 | $15.32M | 0.5% | -4.9% | 6.832% | |
| 5/13/2022 | Vanguard Group Inc. | 710,049 | $4.96M | 0.0% | +122.0% | 2.210% | |
| 5/12/2022 | BlackRock Inc. | 908,164 | $6.34M | 0.0% | +88.6% | 2.826% | |
| 5/12/2022 | Rhumbline Advisers | 12,995 | $91K | 0.0% | N/A | 0.040% | |
| 5/11/2022 | Bank of New York Mellon Corp | 41,688 | $0.29M | 0.0% | +145.6% | 0.130% | |
| 5/11/2022 | JPMorgan Chase & Co. | 12,374 | $86K | 0.0% | -96.2% | 0.039% | |
| 5/10/2022 | Sectoral Asset Management Inc. | 385,069 | $2.69M | 0.5% | +27.8% | 1.198% | |
| 2/9/2022 | AJU IB Investment Co. Ltd. | 754,678 | $7.20M | 10.0% | N/A | 2.349% | |
| 2/8/2022 | Northern Trust Corp | 61,571 | $0.59M | 0.0% | +7.1% | 0.192% | |
| 2/3/2022 | Canaan Partners XI LLC | 2,409,712 | $22.99M | 5.9% | N/A | 7.500% | |
| 1/28/2022 | Allspring Global Investments Holdings LLC | 2,914 | $27K | 0.0% | N/A | 0.009% | |
| 11/16/2021 | Laurion Capital Management LP | 400,000 | $7.03M | 0.0% | N/A | 1.245% | |
| 11/15/2021 | Viking Global Investors LP | 4,194,777 | $73.74M | 0.2% | N/A | 13.056% | |
| 11/15/2021 | Sectoral Asset Management Inc | 527,136 | $9.27M | 0.8% | N/A | 1.641% | |
| 11/15/2021 | Caas Capital Management LP | 10,000 | $0.18M | 0.0% | N/A | 0.031% | |
| 11/12/2021 | New Leaf Venture Partners L.L.C. | 2,301,603 | $40.46M | 11.7% | N/A | 7.163% | |
| 11/12/2021 | Geode Capital Management LLC | 69,963 | $1.23M | 0.0% | N/A | 0.218% | |
| 11/9/2021 | BlackRock Inc. | 292,204 | $5.14M | 0.0% | N/A | 0.909% | |
| 11/4/2021 | Deutsche Bank AG | 4,139 | $73K | 0.0% | N/A | 0.013% | |
| 11/2/2021 | New York State Common Retirement Fund | 4,396 | $77K | 0.0% | N/A | 0.014% | |
Data available starting January 2016
Rallybio Corporation, a clinical-stage biotechnology company, engages in discovering, developing, manufacturing, and delivering therapies that enhance the lives of patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that is in Phase I clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT). The company is also developing RLYB211, a polyclonal anti-HPA-1a antibody that is in a Phase 1/2 clinical trial for the prevention of FNAIT; RLYB114, a pegylated complement factor 5 (C5)-targeted Affibody molecule in preclinical development for the treatment of complement-mediated ophthalmic diseases; and RLYB116, a subcutaneously administered inhibitor of C5 for the treatment of patients with paroxysmal nocturnal hemoglobinuria and generalized myasthenia gravis. Rallybio has collaboration with Exscientia for the development of small molecule therapeutics for rare diseases. Rallybio Corporation was founded in 2018 and is headquartered in New Haven, Connecticut.
Read More on Rallybio
Volume
1,985 shs
Average Volume
111,629 shs
Market Capitalization
$242.27 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
N/A
Who are the company insiders with the largest holdings of Rallybio?
